Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success Wednesday June 11, 11:00 am ET New Medicine's Oncology KnowledgeBASE (nm/OK) tracks the development and use of patient and tumor assessment methodologies that represent one of the most unique opportunities in the oncology field
LAGUNA NIGUEL, Calif., June 11 /PRNewswire/ -- Drug development in oncology is at the threshold of a new era that may finally fulfill the promise of cancer becoming a chronic disease. It is becoming apparent that in order to successfully treat patients with cancer it is necessary to accurately profile their disease and closely and continuously monitor its development. Coupling the use of targeted anticancer agents with patient selection and monitoring using highly specific in vitro tests and/or noninvasive imaging approaches is creating a unique and powerful method for the effective treatment of cancer. New Medicine's Oncology KnowledgeBASE (nm/OK) that has anticipated this trend is a unique resource of every aspect of patient assessment to customize cancer treatment. A unique functionality of nm/OK allows users to specifically retrieve information regarding diagnostic/prognostic approaches by developer and cancer indication; target assessment (overexpression, amplification, mutation, methylation status) by drug, marker, and clinical trial protocol; and biomarkers for clinical trial surrogate endpoints, among others.
There are over 1,000 molecular targets linked to some aspect of neoplasia currently in preclinical or clinical development or on the market. Among the approximately 500 novel molecularly targeted agents that have been evaluated in clinical trials (multitargeted agents may appear in several groups) are:
41 agents targeting the vascular endothelial growth factor (VEGF) pathway 18 agents targeting the ErBb family (EGFr, HEr2, etc.) 13 agents targeting the Aurora kinase family 11 histone deacetylase inhibitors (HDAC) 13 agents targeting PDGF/PDGFr 11 agents targeting various heat shock proteins (Hsp) 10 drugs targeting various cyclin-dependent kinases (Cdk) 10 agents targeting c-Met 10 agents targeting IGF/IGFr 10 agents targeting FLT-3 9 agents targeting c-Kit
New Medicine's Oncology KnowledgeBASE (nm|OK), residing at http://www.nmok.net, provides a complete knowledge environment in drug development in cancer. Contact us for an online demonstration of nm|OK.